SET binding protein 1 (SETBP1)

SET binding protein 1 (SETBP1) is a nuclear DNA-binding protein acting as a transcription factor and epigenetic regulator in humans[1][2][5]. SETBP1 is involved in chromatin remodeling, facilitating gene expression by making chromatin more accessible through histone methylation. It forms part of multiprotein complexes, notably binding to SET—a nuclear oncogene involved in histone modification and inhibition of the tumor suppressor PP2A[3]. Through its AT-hook DNA-binding domains, SETBP1 regulates transcription of crucial developmental genes, including promoters for HOXA9, HOXA10, and RUNX1 in hematopoietic cells[4]. Mutations in SETBP1 are clinically significant—gain-of-function mutations drive oncogenesis (especially in atypical chronic myeloid leukemia), while loss-of-function mutations result in neurodevelopmental disorders such as Schinzel–Giedion syndrome and SETBP1 haploinsufficiency disorder[1][5]. SETBP1's function is tightly linked to both cell proliferation and differentiation, and its dysregulation contributes to cancer pathogenesis and diverse syndromic childhood diseases. Currently, there are no approved therapies that directly target SETBP1, but its central regulatory role makes it an important candidate for future therapeutic research.

Other names

SETBP1SET-binding proteinKIAA0437SEBMRD29

Inhibition of SETBP1/SET complex to reactivate PP2A tumor suppressor activity (hypothetical/under research); Disruption of histone methylation/chromatin accessibility to suppress oncogenic transcription programs; Modulation of transcriptional networks involved in stem cell signatures and differentiation; Not yet targeted by FDA-approved drugs